Open this publication in new window or tab >>2026 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]
Novel synthetic compounds that are designed to mimic the effects of traditional drugs of abuse are known as new psychoactive substances (NPS). Specifically designed to circumvent national and international legislation, they emerge on illicit drug markets at an approximate rate of ~1 new compound per week. Their rapid appearance, structural diversity, and limited prior knowledge regarding their metabolism, pharmacological activity, toxicity, and detectability pose challenges for public health, forensic toxicology, healthcare systems, and regulatory authorities. Therefore, characterisation of emerging NPS is essential to support risk assessment, analytical detection, and clinical management of intoxications. This thesis investigates previously scarcely characterised NPS and fills the knowledge gap of missing basic pharmacological characterisation, with a particular focus on synthetic cannabinoid receptor agonists (SCRAs) and synthetic stimulants.
With human hepatocyte incubations, the metabolism of several fluorinated SCRAs was characterised, and using synthesised reference standards of other SCRAs, the structural confirmation of selected metabolites was confirmed. To improve understanding of biological activity, pharmacodynamic studies were conducted of selected SCRA metabolites and a large group of synthetic stimulants, including synthetic cathinones. The activity of SCRAs and their metabolites was investigated at the cannabinoid receptor 1 (CB1), while synthetic stimulants were characterised on dopamine, norepinephrine, and serotonin reuptake transporters (DAT, NET, and SERT). In addition, an untargeted metabolomics workflow using SH-SY5Y neuronal cells was developed to investigate cellular responses following NPS exposure. Distinct metabolomic fingerprints were observed for different drugs of abuse, including some NPS.
The findings present metabolite profiles of SCRAs, show the potential of metabolites contributing to cannabimimetic effects of their parent compounds, demonstrate synthetic stimulant group-wise inhibition patterns at transporters, and present the potential of an untargeted metabolomics method as a complementary approach for studying biological effects of NPS beyond cellular target interactions.
The findings contribute to improved analytical detections, expand current knowledge of NPS' pharmacological activity and structure-activity relationships, and support ongoing efforts to strengthen evidence-based risk assessment of newly emerging psychoactive substances.
Place, publisher, year, edition, pages
Linköping: Linköping University Electronic Press, 2026. p. 61
Series
Linköping University Medical Dissertations, ISSN 0345-0082 ; 2057
Keywords
New psychoactive substances, Synthetic cannabinoid receptor agonists, Synthetic stimulants, Metabolism, Human hepatocytes, CB1 receptor, 5-HT2A receptor, Monoamine transporters, Metabolomics, UHPLC-QToF-MS
National Category
Pharmacology and Toxicology
Identifiers
urn:nbn:se:liu:diva-229112 (URN)10.3384/9789181186475 (DOI)9789181186468 (ISBN)9789181186475 (ISBN)
Public defence
2026-12-04, Hasselquistsalen, Building 511/001, Campus US, Linköping, 13:00 (English)
Opponent
Supervisors
2026-11-032026-11-032026-11-03Bibliographically approved